» Articles » PMID: 36641921

Diabetic Nephropathy: Focusing on Pathological Signals, Clinical Treatment, and Dietary Regulation

Overview
Date 2023 Jan 15
PMID 36641921
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetic nephropathy (DN) is one of the most severe complications of diabetes. However, due to its complex pathological mechanisms, no effective therapeutic methods (other than ACEIs and ARBs) have been applied, which have been used for many years in clinical practice. Recent studies have shown that emerging therapeutics, including novel target-based pharmacotherapy, cell therapies, and dietary regulation, are leading to new hopes for DN management. This review aims to shed new light on the treatment of DN by describing the important pathological mechanisms of DN and by analysing recent advances in clinical treatment, including drug therapy, cell therapy, and dietary regulation. In pathological mechanisms, RAAS activation, AGE accumulation, and EMT are involved in inflammation, cellular stress, apoptosis, pyroptosis, and autophagy. In pharmacotherapy, several new therapeutics, including SGLT2 inhibitors, GLP-1 agonists, and MRAs, are receiving public attention. In addition, stem cell therapies and dietary regulation are also being emphasized. Herein, we highlight the importance of combining therapy and dietary regulation in the treatment of DN and anticipate more basic research or clinical trials to verify novel strategies.

Citing Articles

Glucosyl Hesperidin Supplementation Prevents Tubulointerstitial Fibrosis and Immune Activation in Diabetic Nephropathy in Mice.

Hashimoto K, Yoshida Y, Kamesawa M, Yazawa N, Tominaga H, Aisyah R Nutrients. 2025; 17(3).

PMID: 39940240 PMC: 11820413. DOI: 10.3390/nu17030383.


Curcumin nanocrystals ameliorate ferroptosis of diabetic nephropathy through glutathione peroxidase 4.

Xue M, Tian Y, Zhang H, Dai S, Wu Y, Jin J Front Pharmacol. 2025; 15():1508312.

PMID: 39834811 PMC: 11743454. DOI: 10.3389/fphar.2024.1508312.


FSTL1 aggravates high glucose-induced oxidative stress and transdifferentiation in HK-2 cells.

Zhang B, Geng H, Zhao K, Omorou M, Liu S, Ye Z Sci Rep. 2025; 15(1):434.

PMID: 39748077 PMC: 11696259. DOI: 10.1038/s41598-024-84462-5.


Targeting programmed cell death in diabetic kidney disease: from molecular mechanisms to pharmacotherapy.

Liu F, Yang Z, Li J, Wu T, Li X, Zhao L Mol Med. 2024; 30(1):265.

PMID: 39707216 PMC: 11660506. DOI: 10.1186/s10020-024-01020-5.


Diphenyl diselenide protects against diabetic kidney disease through modulating gut microbiota dysbiosis in streptozotocin-induced diabetic rats.

Wang X, Long D, Peng X, Li J, Zhou M, Wang Y Front Pharmacol. 2024; 15:1506398.

PMID: 39697537 PMC: 11653185. DOI: 10.3389/fphar.2024.1506398.